{"url_path":"/sec/vyne/8-k/2026-07-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-083356-index.html","accession_number":"0001104659-26-083356","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-083356-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":727,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation FD Disclosure.**\n\n \n\nOn July 14, 2026, Yarrow Bioscience, Inc. (“Yarrow”)\npublished an investor presentation (the “Presentation”) that it plans to use for investor relations and other purposes. VYNE\nTherapeutics Inc. (“VYNE”) has also made the Presentation available on the Investor portion of its website at https://vynetherapeutics.com/investors-media/events_presentations/.\nA copy of the Presentation is attached as Exhibit 99.1.\n\n \n\nThe information in this Item 7.01 and Exhibit 99.1\nhereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,\nas amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated\nby reference in any of VYNE’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set\nforth by specific reference in such filing.\n\n \n\n**No Offer or Solicitation**\n\n \n\nThis Current Report on Form 8-K and the exhibit\nfurnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities\nor in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation\nto purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or\ntransfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of\na prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by\nthe relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction\nwhere to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality\n(including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility\nof a national securities exchange, of any such jurisdiction.\n\n \n\nNEITHER THE UNITED STATES SECURITIES AND EXCHANGE\nCOMMISSION (THE “SEC”) NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF\nTHIS CURRENT REPORT ON FORM 8-K AND THE EXHIBIT FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.\n\n \n\n \n\n \n\n \n\n**Important Additional Information About the Proposed Transaction\nHas Been Filed with the SEC**\n\n \n\nThis Current Report on Form 8-K does not substitute\nfor the S-4 (as defined below), proxy statement/prospectus or for any other document that VYNE has filed or may file with the SEC in connection\nwith the proposed transaction. In connection with the proposed transaction between VYNE and Yarrow, VYNE has filed relevant materials\nwith the SEC, including a registration statement on Form S-4 (File No.: 333-294804) that contains a proxy statement/prospectus (the “S-4”).\nVYNE URGES INVESTORS AND STOCKHOLDERS TO READ THE S-4, INCLUDING THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN, AND ANY OTHER RELEVANT\nDOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY\nBECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT VYNE, YARROW, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders\nwill be able to obtain free copies of the S-4 and other documents filed by VYNE with the SEC through the website maintained by the SEC\nat *www.sec.gov*. In addition, investors and stockholders should note that VYNE communicates with investors and the public using\nits website (*www.vynetherapeutics.com*) and the investor media website (*https://vynetherapeutics.com/investors-media*) where\nanyone will be able to obtain free copies of the S-4 and included proxy statement/prospectus and other documents filed by VYNE with the\nSEC and stockholders are urged to read the S-4 and included proxy statement/prospectus and the other relevant materials before making\nany voting or investment decision with respect to the proposed transaction.\n\n \n\n**Participants in the Solicitation**\n\n \n\nVYNE, Yarrow and their respective directors and\nexecutive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the proposed transaction.\nInformation about VYNE’s directors and executive officers, including a description of their interests in VYNE, is included in the\nS-4 and VYNE’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 27, 2026.\nThese documents are available free of charge at the SEC's website at www.sec.gov."}